179 related articles for article (PubMed ID: 15023541)
1. Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer.
Demetriou MC; Pennington ME; Nagle RB; Cress AE
Exp Cell Res; 2004 Apr; 294(2):550-8. PubMed ID: 15023541
[TBL] [Abstract][Full Text] [Related]
2. Integrin alpha6 cleavage: a novel modification to modulate cell migration.
Pawar SC; Demetriou MC; Nagle RB; Bowden GT; Cress AE
Exp Cell Res; 2007 Apr; 313(6):1080-9. PubMed ID: 17303120
[TBL] [Abstract][Full Text] [Related]
3. Integrin clipping: a novel adhesion switch?
Demetriou MC; Cress AE
J Cell Biochem; 2004 Jan; 91(1):26-35. PubMed ID: 14689578
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
[TBL] [Abstract][Full Text] [Related]
5. Macrophage-dependent cleavage of the laminin receptor α6β1 in prostate cancer.
Sroka IC; Sandoval CP; Chopra H; Gard JM; Pawar SC; Cress AE
Mol Cancer Res; 2011 Oct; 9(10):1319-28. PubMed ID: 21824975
[TBL] [Abstract][Full Text] [Related]
6. Integrin A6 Cleavage in Mouse Skin Tumors.
Demetriou MC; Kwei KA; Powell MB; Nagle RB; Bowden GT; Cress AE
Open Cancer J; 2008 Jan; 2():1-4. PubMed ID: 20664806
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
8. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
9. Extracellular engagement of alpha6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis.
Ports MO; Nagle RB; Pond GD; Cress AE
Cancer Res; 2009 Jun; 69(12):5007-14. PubMed ID: 19491258
[TBL] [Abstract][Full Text] [Related]
10. In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin.
Festuccia C; Guerra F; D'Ascenzo S; Giunciuglio D; Albini A; Bologna M
Int J Cancer; 1998 Jan; 75(3):418-31. PubMed ID: 9455804
[TBL] [Abstract][Full Text] [Related]
11. Intracellular modifiers of integrin alpha 6p production in aggressive prostate and breast cancer cell lines.
Kacsinta AD; Rubenstein CS; Sroka IC; Pawar S; Gard JM; Nagle RB; Cress AE
Biochem Biophys Res Commun; 2014 Nov; 454(2):335-40. PubMed ID: 25450398
[TBL] [Abstract][Full Text] [Related]
12. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
13. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation.
Tarui T; Akakura N; Majumdar M; Andronicos N; Takagi J; Mazar AP; Bdeir K; Kuo A; Yarovoi SV; Cines DB; Takada Y
Thromb Haemost; 2006 Mar; 95(3):524-34. PubMed ID: 16525582
[TBL] [Abstract][Full Text] [Related]
14. Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines.
Al-Ejeh F; Croucher D; Ranson M
Exp Cell Res; 2004 Jul; 297(1):259-71. PubMed ID: 15194441
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.
Czekay RP; Aertgeerts K; Curriden SA; Loskutoff DJ
J Cell Biol; 2003 Mar; 160(5):781-91. PubMed ID: 12615913
[TBL] [Abstract][Full Text] [Related]
16. Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells.
Bekes EM; Deryugina EI; Kupriyanova TA; Zajac E; Botkjaer KA; Andreasen PA; Quigley JP
Neoplasia; 2011 Sep; 13(9):806-21. PubMed ID: 21969814
[TBL] [Abstract][Full Text] [Related]
17. Regulation of human squamous cell carcinoma plasma membrane associated urokinase plasminogen activator by epidermal growth factor.
Niedbala MJ; Bajetta S; Carbone R; Sartorelli AC
Cancer Commun; 1990; 2(9):317-24. PubMed ID: 2169831
[TBL] [Abstract][Full Text] [Related]
18. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
Mamoune A; Kassis J; Kharait S; Kloeker S; Manos E; Jones DA; Wells A
Exp Cell Res; 2004 Sep; 299(1):91-100. PubMed ID: 15302576
[TBL] [Abstract][Full Text] [Related]
19. Pro-urokinase-type plasminogen activator is a substrate for hepsin.
Moran P; Li W; Fan B; Vij R; Eigenbrot C; Kirchhofer D
J Biol Chem; 2006 Oct; 281(41):30439-46. PubMed ID: 16908524
[TBL] [Abstract][Full Text] [Related]
20. The role of alpha 6 integrin in prostate cancer migration and bone pain in a novel xenograft model.
King TE; Pawar SC; Majuta L; Sroka IC; Wynn D; Demetriou MC; Nagle RB; Porreca F; Cress AE
PLoS One; 2008; 3(10):e3535. PubMed ID: 18958175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
